Grégoire Martin de Frémont
LightNews LightNews
banner
gregoiremdf.bsky.social
Grégoire Martin de Frémont
@gregoiremdf.bsky.social
97 followers 200 following 2 posts
MD @APHP - PhD student @KarolinskaInstitutet
Posts Replies Media Videos
Reposted by Grégoire Martin de Frémont
rheumnow.bsky.social
Swedish Medical Birth Register study of pregnancy in systemic sclerosis (SSc) shows increased risk of preeclampsia (RR 3.8; 1.8-7.8), preterm birth (3.3; 1.8-6.1), & caesareans (2.5; 1.8-3.5) esp w/ 1st pregnancy acrjournals.onlinelibrary.wiley.com/doi/10.1002/...
July 11, 2025 at 2:02 PM
Reposted by Grégoire Martin de Frémont
bethangoulden.bsky.social
Also great to see further reassuring data for anakinra in pregnancy, now out from France academic.oup.com/rheumatology...
Exposure during pregnancy to Il-1 targeted therapies and pregnancy, fetal and neonatal outcomes: a study from the French Teratology Information Service
AbstractOBJECTIVE. To describe the outcomes of pregnancies exposed to IL-1 targeted therapies (anti-IL-1): anakinra and/or canakinumab.METHODS. We performe
academic.oup.com
July 14, 2025 at 7:06 AM
Reposted by Grégoire Martin de Frémont
natrevrheum.nature.com
New content online:
Platelets as drivers of immunothrombosis in rheumatic diseases
Nature Reviews Rheumatology, Published online: 07 July 2025; doi:10.1038/s41584-025-01276-zThis Review provides an overview of how platelets promote immunothrombosis in rheumatic disease. The authors discuss the different ways in which platelets and immunothrombosis can be targeted for therapeutic intervention.
bit.ly
July 7, 2025 at 1:31 PM
Reposted by Grégoire Martin de Frémont
revmedinterne.bsky.social
ℹ️ Mise au point
Quelle place de la protéine ADAMTS13 recombinante humaine dans le traitement du purpura thrombotique thrombocytopénique ? Retrouvez les recommendations du CNR des microangiopathies thrombotiques sur les indications et modalités d’administration👇

www.sciencedirect.com/science/arti...
July 7, 2025 at 1:49 PM
Reposted by Grégoire Martin de Frémont
natrevrheum.nature.com
✨July Issue✨| Monogenic systemic vasculitis

In this Review, the authors discuss the pathogenesis, clinical presentations and treatment of monogenic systemic vasculitis.

Free to read: bit.ly/3I0cw14 🔓

#Rheumsky #Medsky
The pathogenesis, clinical presentations and treatment of monogenic systemic vasculitis
Nature Reviews Rheumatology - This Review discusses the clinical features, pathogenesis, diagnosis and management of monogenic forms of vasculitis. The authors emphasize that increased awareness of...
bit.ly
June 26, 2025 at 8:28 AM
Reposted by Grégoire Martin de Frémont
revmedinterne.bsky.social
Le 90ème Congrès #SNFMI débute demain à #Vichy
snfmivichy2025.com

Découvrez d'ores et déjà l'ensemble des résumés de Communications dans notre Numéro spécial Congrès : www.sciencedirect.com/journal/la-r...
La Revue de Médecine Interne | 90e CONGRÈS FRANÇAIS DE MÉDECINE INTERNE - Vichy, 25 au 27 juin 2025 | ScienceDirect.com by Elsevier
Read the latest articles of La Revue de Médecine Interne at ScienceDirect.com, Elsevier’s leading platform of peer-reviewed scholarly literature
www.sciencedirect.com
June 24, 2025 at 4:10 PM
Reposted by Grégoire Martin de Frémont
revmedinterne.bsky.social
French protocol for diagnosis and management of type 1 interferonopathies

www.sciencedirect.com/science/arti...
June 22, 2025 at 11:33 AM
Reposted by Grégoire Martin de Frémont
acr-journals.bsky.social
Inflammatory response to UVB exposure in Trim21-/- mice
doi.org/10.1002/art....

Open-label trial of escalation to golimumab in early axSpA gut inflammation
doi.org/10.1002/art....
Loss of TRIM21 drives UVB‐induced systemic inflammation by regulating DNA‐sensing pathways
Background Patients with systemic lupus erythematosus (SLE) experience photosensitivity, with exposure to ultraviolet light B (UVB) driving lupus flares and triggering symptoms like joint pain, fati...
doi.org
June 21, 2025 at 2:07 PM
Reposted by Grégoire Martin de Frémont
thelancetrheum.bsky.social
Our July issue is live!

Including research on patient-reported outcomes in #SLE, #SystemicSclerosis associated #ILD, autoimmune diseases during #pregnancy, and treatment outcomes in #VEXAS syndrome, plus much more! www.thelancet.com/journals/lan...
Cover by Sara Gironi Carnevale #Medsky #Rheumsky
June 17, 2025 at 9:33 AM
Reposted by Grégoire Martin de Frémont
nejm.org
Two patients had autoimmune hemolytic anemia that relapsed after CD19 CAR T-cell therapy but responded rapidly to BCMA-targeted T-cell–engager therapy with remission, minimal side effects, and hematologic improvement. Learn more: nej.md/3SM6S4V

#MedSky #Immunology
The clinical responses in Patients 1 and 2 before and after the first dose of CM336 through 6 months.
June 16, 2025 at 4:01 PM
Reposted by Grégoire Martin de Frémont
thelancetrheum.bsky.social
NEW RESEARCH—Exposure to #hydroxychloroquine in early #pregnancy and incidence of pre-eclampsia and pre-term delivery in patients with systemic #lupus erythematosus in Sweden: a nationwide population-based cohort study bit.ly/3FBPz3J @rheumepi.bsky.social

Plus, linked Comment bit.ly/3Tknh0D
June 13, 2025 at 6:00 AM
Reposted by Grégoire Martin de Frémont
thelancetrheum.bsky.social
NEW RESEARCH—Trends in the prevalence of autoimmune diseases during #pregnancy in the UK, 2000–21: a retrospective cohort study bit.ly/449fPe3 #Medsky #Rheumsky

Plus linked Comment by @hilarykbrown.bsky.social & @nataliescime.bsky.social bit.ly/3HrIPps
June 4, 2025 at 4:35 PM
Reposted by Grégoire Martin de Frémont
natrevrheum.nature.com
New content online:
Advances in the treatment of ANCA-associated vasculitis
Nature Reviews Rheumatology, Published online: 05 June 2025; doi:10.1038/s41584-025-01266-1This Review discusses the advances and challenges of managing antineutrophil cytoplasmic antibody-associated vasculitis. The authors discuss current treatment options, emerging therapies and unmet needs in the management of this disease.
bit.ly
June 5, 2025 at 11:32 AM
Reposted by Grégoire Martin de Frémont
nejm.org
Late breaking at #ASCO25:

A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial: nej.md/4mh5RPL

@ascocancer.bsky.social
June 1, 2025 at 12:05 PM
Reposted by Grégoire Martin de Frémont
thelancetrheum.bsky.social
NEW RESEARCH for #LUPUS2025 —Maternal autoantibodies to the sodium potassium pump α1 subunit AT1A1 and fetal autoimmune congenital heart block: a case-control study bit.ly/43lRzol

Plus, linked Comment bit.ly/3STJLoV
#Medsky #Rheumsky
May 22, 2025 at 1:33 PM
Reposted by Grégoire Martin de Frémont
revmedinterne.bsky.social
🖼️Portrait
Découvrez Alexandre Belot, PUPH en rhumatologie pédiatrique et co-coordinateur de la filière FAI2R, ainsi que son regard sur la médecine interne et son avenir.

www.sciencedirect.com/science/arti...
Portrait du Pr Alexandre Belot, PU-PH en rhumatologie pédiatrique au CHU de Lyon, co-coordinateur de la filière FAI2R
www.sciencedirect.com
May 21, 2025 at 7:24 PM
Reposted by Grégoire Martin de Frémont
natureportfolio.nature.com
A Review in Nature Reviews Immunology provides an overview of the current vaccines that are offered during pregnancy and to newborns, explaining the rationale behind the different vaccination programmes and the unique challenges that come with immunizing these populations. 🔒
Vaccination in pregnancy to protect the newborn - Nature Reviews Immunology
In this Review, Male and Jones provide an overview of the current vaccines that are offered during pregnancy and to newborns, explaining the rationale behind the different vaccination programmes and the unique challenges that come with immunizing these populations.
go.nature.com
May 18, 2025 at 1:50 PM
Reposted by Grégoire Martin de Frémont
hopitalcochin.bsky.social
🔬Du 12 au 17 mai, @ap-hp.bsky.social célèbre celles et ceux qui font avancer la recherche pour améliorer les soins et donner de l’espoir aux patients. #recherche #recherchemedicale #rhumatologie #spondyloarthritis #spondyloarthrite
May 12, 2025 at 11:16 AM
Reposted by Grégoire Martin de Frémont
silvia-aps.bsky.social
🤔Missed any #RheumaPreg25 sessions?
No worries! Join the highlights webinar on May 26. Contact @karenschreiber.bsky.social or @lauraandreoli.bsky.social to join the #ReHFaP mailing list 📩
May 10, 2025 at 10:59 AM
Reposted by Grégoire Martin de Frémont
revmedinterne.bsky.social
⚖️ Faut il traiter le lymphome du MALT dans la maladie de Sjögren?

✅Pour?
www.sciencedirect.com/science/arti...

🚫Contre?
www.sciencedirect.com/science/arti...
« Faut-il traiter le lymphome du MALT dans la maladie de Sjögren ? » : le pour
www.sciencedirect.com
May 7, 2025 at 2:10 PM
Reposted by Grégoire Martin de Frémont
revmedinterne.bsky.social
⚖️ Inauguration de la rubrique « Controverse » ce mois ci dans la Revue de Médecine Interne

www.sciencedirect.com/science/arti...
La « Controverse », l’heure du staff dans la revue de médecine interne
www.sciencedirect.com
May 7, 2025 at 2:07 PM
Reposted by Grégoire Martin de Frémont
nejm.org
Both clonal hematopoiesis of indeterminate potential (CHIP) and cancer are more common with age. When they coexist in the same patient, CHIP cells may migrate to the tumor and have an adverse effect on overall survival. Full study results: nej.md/3EnzMVu

#MedSky #Hematology
A schematic representation of clonal hematopoiesis of indeterminate potential (CHIP) and tumor-infiltrating clonal hematopoiesis (TI-CH) in a patient with lung cancer.
April 27, 2025 at 1:21 PM
Reposted by Grégoire Martin de Frémont
erictopol.bsky.social
Reducing the risk of all-cause dementia with intensive blood pressure control, the results of a cluster randomized trial in~34,000 participants. @naturemedicine.bsky.social
www.nature.com/articles/s41...
Blood pressure reduction and all-cause dementia in people with uncontrolled hypertension: an open-label, blinded-endpoint, cluster-randomized trial - Nature Medicine
In the CRHCP-3 cluster-randomized trial, blood pressure reduction lowered the risk of all-cause dementia by 15% in 33,995 individuals with hypertension.
www.nature.com
April 21, 2025 at 3:58 PM
Reposted by Grégoire Martin de Frémont
acr-journals.bsky.social
Multicenter cohort trial emulation tested TMP-SMX prophylaxis on incidence of serious infections in pts w/ ANCA-associated vasculitis. TMP-SMX significantly reduced risk of serious infections, esp. during 1st 6 mo. of induction therapy w/ RTX or CYC

A&R
doi.org/10.1002/art....
#Medsky #Rheum #IDsky
Time-dependent effect of prophylactic trimethoprim-sulfamethoxazole on the incidence of serious infections in ANCA-associated vasculitis: A target trial emulation study. Graphical abstract created with BioRender
April 21, 2025 at 8:19 PM
Reposted by Grégoire Martin de Frémont
nejm.org
In the REGENCY phase 3 trial, obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, plus standard therapy provided significantly better renal responses than standard therapy alone in patients with lupus nephritis. Full trial results and Research Summary: nej.md/3Eq6gxV

#MedSky
The New England Journal of Medicine Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis A Research Summary based on Furie RA et al. | 10.1056/NEJMoa2410965 | Published on February 7, 2025 Visual representations of the patients in the trial and the treatments they were assigned. Read the full Research Summary at NEJM.org.
April 20, 2025 at 7:01 PM